"Two research groups say they've independently built quantum devices that can operate at temperatures above 1 Kelvin — 15 times hotter than rival technologies can withstand," reports IEEE Spectrum. (In an article shared by Slashdot reader Wave723.)

"The ability to work at higher temperatures is key to scaling up to the many qubits thought to be required for future commercial-grade quantum computers..." HongWen Jiang, a physicist at UCLA and a peer reviewer for both papers, described the research as "a technological breakthrough for semiconductor based quantum computing." In today's quantum computers, qubits must be kept inside large dilution refrigerators at temperatures hovering just above absolute zero. Electronics required to manipulate and read the qubits produce too much heat and so remain outside of the fridge, which adds complexity (and many wires) to the system...

"To me, these works do represent, in rapid succession, pretty big milestones in silicon spin qubits," says John Gamble, a peer reviewer for one of the papers and a senior quantum engineer at Microsoft. "It's compelling work...." Moving forward, Gamble is interested to see if the research groups can scale their approach to include more qubits. He's encouraged by their efforts so far, saying, "The fact that we're seeing these types of advances means the field is progressing really well and that people are thinking of the right problems."
Besides Microsoft, Google and IBM have also "invested heavily in superconducting qubits," the article points out. And there's also a hopeful comment from Lee Bassett, a physicist focused on quantum systems at the University of Pennsylvania. "Each time these silicon devices pass a milestone — and this is an important milestone — it's closer and closer to the inflection point.

"This infrastructure of integrated, silicon-based electronics could take over, and this technology could just explode."

Newsweek reports: There is no evidence to back claims the coronavirus that has caused the COVID-19 pandemic emerged from a lab in China, scientists have told Newsweek.

Adam Lauring, an associate professor at the University of Michigan Medical School and an expert in the evolution of viruses, told Newsweek: "This claim is a conspiracy theory and it is not supported at all by the available data... The SARS-CoV-2 virus has some key differences in specific genes relative to previously identified coronaviruses — the ones a laboratory would be working with," said Lauring. "This constellation of changes makes it unlikely that it is the result of a laboratory 'escape.'"

Alexandre Hassanin, a lecturer at France's Sorbonne University National Museum of Natural History department of origins and evolution, similarly highlighted to Newsweek: "Even if it is difficult to prove that a laboratory accident did not take place, you should know that SARS-CoV-2 is not closely related to any previous viruses; it was never sequenced (even partially) in previous studies, and the COVID-19 outbreak began in November/December, as in previous SARS epidemic events (2002 and 2003)."

Hassanin said: "These two points suggest therefore that the current outbreak was not the consequence of a laboratory accident."
An anonymous reader adds: Today the Associated Press also called it "an outlier theory" being spread by president Trump and officials in his administration "without the weight of evidence."

On Twitter, Eric Hundman, an Assistant Professor at NYU Shanghai, had stern words for anyone still spreading this misinformation. "Insinuating that the virus escaped from a lab in China by saying 'well, there's no evidence that it didn't' is not only untrue, it amounts to disinformation that could further ratchet up US-China tensions and distract from more urgent priorities.

*There actually is scientific evidence against the "escaped from a lab" theory."
He then cites five different scientists who wrote in Nature magazine that "We do not believe that any type of laboratory-based scenario is plausible."

In fact, "Most experts push back on the lab leak theory," CNN reported earlier this month. "I think it has no credibility," they were told by Vincent Racaniello, a microbiology professor at Columbia University who hosts a podcast called "This Week in Virology."

And they got the same response from Dr. Simon Anthony, a professor at the public health grad school of Columbia University and a key member of PREDICT. "It all feels far-fetched. Lab accidents do happen, we know that, but... there's certainly no evidence to support that theory."

That's also the opinion of America's intelligence community. Business Insider writes: The US intelligence community has also been investigating whether the virus was collected by researchers and then accidentally leaked from a Chinese lab but has found no evidence to date backing it up, according to Politico, which cited multiple sources familiar with the matter. Or, as Politico puts it: Congressional intelligence committees have been asking various agencies if hard evidence exists to support it. So far, there is none, multiple sources familiar with the matter told POLITICO.
UPDATE (4/19/20): On Sunday even Dr. Deborah Birx, the White House's Coronavirus Task Force response coordinator, acknowledged "I don't have evidence that it was a laboratory accident."

GeekWire reports: The University of Washington School of Medicine's Virology Lab is reporting encouraging results from trial runs of a new test from Abbott Laboratories that detects the antibodies created by people who have had COVID-19, whether they knew they had it or not. "This is a really fantastic test," Keith Jerome, who leads UW Medicine's virology program, told reporters today. He said UW's lab could process 4,000 samples per day starting next week, and conceivably ramp up to 14,000 samples per day within a couple of weeks.

The test will be made available through health care providers, in medical clinics or perhaps through workplaces... Epidemiologists say knowing who has had the virus will be key to tracking the true spread of COVID-19, and giving assurances to people who are returning to school and work — particularly in front-line jobs ranging from first responders and health care workers to grocery store clerks.

"It's possible this could be part of a back-to-work process," Jerome said. It's not yet clear how much immunity people develop to COVID-19 in the course of fighting off the virus, but if SARS-CoV-2 behaves like other coronaviruses, people with antibodies should have at least some protection from re-infection...

There's also a chance that being able to detect antibodies for COVID-19 will speed the development of vaccines in the months ahead.
1 million of the tests will be shipped this week in the U.S., and up to 4 million in the month of April, GeekWire reports.

And by June the company plans to be shipping 20 million tests per month.

This week the Washington Post asked their "business of health care" reporter to explain the true status in the scientific community of hydroxychloroquine, an already-approved malaria drug also used to control inflammation in lupus and rheumatoid arthritis patients.

"There is no clear evidence that the drugs work against the coronavirus," he writes, "despite their use by hospitals and doctors in the United States and other countries since the outbreak began." Their antiviral properties have been proved in test tubes, but rigorous clinical trials to test their effectiveness in humans have not been completed. Limited studies on coronavirus patients have been published by researchers in France and China, but their extremely small size and other problems prevented them from being statistically significant. The French study included a combination of hydroxychloroquine with the antibiotic azithromycin that showed benefit in six patients... Another study in 11 patients in France showed no evidence the regimen works. A Chinese study also showed no benefit over the standard course of treatment.

Mainstream scientists caution against using the drugs without more evidence they are effective... The dangerous side effects of the drugs are much better known. Most seriously, the drugs can trigger arrhythmia, which can lead to a fatal heart attack in patients with cardiovascular disease or who are taking certain drugs, including anti-depression medications. Doctors recommend screening with an electrocardiogram to prevent the drug from being given to the 1 percent of patients at the greatest risk of a cardiac event. The drugs also can cause vision loss called retinopathy with long-term use, and chloroquine has been associated with psychosis...

As the coronavirus has spread from China across the world and to the United States, the dire reality is that there is no vaccine and no approved drug available to treat the serious respiratory symptoms that are claiming thousand of lives.
Long-time Slashdot reader UnknowingFool shares doubts raised about that small French study, as even its publisher now acknowledges it "does not meet" their own expected standards.

The Post does note that multiple trials are "ongoing" (though six different research centers testing the drug told CNN it would be "months" before results were known). But the Post adds that already "public and political interest has caused runs, hoarding and severe shortages in recent weeks."

The New York Post reports that a COVID-19 vaccine "may be six months away, according to a researcher leading a team of scientists in England." "I think there's a high chance that it will work based on other things that we have done with this type of vaccine," Sarah Gilbert, a professor of virology at Oxford told The Times of London. "It's not just a hunch and as every week goes by we have more data to look at. I would go for 80 percent, that's my personal view."
Gilbert added that if they can find places that haven't imposed a lockdown, "we will get our efficacy results very quickly."

America and Israel have also reported encouraging progress on a vaccine. And in the Netherlands and Australia, researchers are testing the effectiveness of the BCG tuberculosis vaccine developed in the 1920s (with more tests being scheduled for Africa, and experiments in the U.K.) UPI reports researchers in the Netherlands "have started recruiting 1,000 healthcare workers, who are at high risk for COVID-19, in eight hospitals who will receive either the BCG vaccine or a placebo."

The Times of London reports that the U.K. government "signalled that it would be willing to fund the manufacture of millions of doses in advance" if the results of professor Gilbert's research looked promising. "This would allow it to be available immediately to the public if it were proven to work.

"With ministers struggling to find a strategy to exit the lockdown, long-term hopes of a return to normality rely on a vaccine."

"Apple announced Sunday it's launched a companywide effort to design, produce and ship face shields to medical workers battling the coronavirus outbreak," reports CNET: The first shipment was delivered this week to a Kaiser facility in the Santa Clara Valley, Apple CEO Tim Cook said in a video posted to Twitter.

"Teams across Apple have been working hard on ways we can support our heroic front-line medical professionals," Cook said, explaining that the fully adjustable shields pack flat and can be assembled in two minutes. "The feedback from doctors was very positive." "We plan to ship over 1 million by the end of this week, and over 1 million per week after that," he said. Cook said the company is coordinating with health and government officials across the US to get the shields delivered where they're needed and hopes to expand distribution beyond the US quickly.
"Apple is dedicated to supporting the worldwide response to COVID-19," Apple's CEO said on Twitter. "We've now sourced over 20M masks through our supply chain."

Elon Musk shared a new video today from Tesla Engineering. "We're trying to make some ventilators from some car parts, so we can help the medical industry without taking away from their supply," it begins. (All three people who appear in the video are wearing a face mask.)

It ends with a demonstration of a prototype using a touchscreen display from the Model 3 infotainment system. "There's still a lot of work to do," the video concludes, "but we're giving it our best effort to make sure we can help some people out there."

Yesterday ventilator manufacturer Medtronic also tweeted that Musk's other company SpaceX "is now making a vital component for critical care ventilators," meaning more of the devices would arrive sooner for Covid-19 patients.

Meanwhile, the New York Post writes: Musk promised last month to shift production to the sorely-needed medical devices, but evidently found that buying existing ventilators with his own largesse was more practical. He shelled out to send 1,000 of the life-saving machines to California, and also vowed to buy some for New York, earning the gratitude of Mayor Bill de Blasio. Musk made good, with the city's public hospital system on Saturday tweeting their gratitude for ventilators Tesla donated, now in use at Lincoln Hospital in The Bronx.

But, with the apex of the contagion possibly upon New York, Cuomo said Sunday that time had run out for Tesla to make new ventilators. "Their time-frame, frankly, doesn't work for our immediate apex, because whether we're talking two days or 10 days, you're not going to make ventilators at that time," said Cuomo, noting that the hang-up is that some parts have to come from overseas.

"From face-shields to respirator valves, 3-D printer owners pitch in to the efforts to provide PPE to Australian hospitals," writes davecb (Slashdot reader #6,526).

It's not only happening in Australia. But the Guardian talked to Mat Bowtell, a former Toyota engineer in Australia who's using fourteen 3D printers to manufacture thousands of face shields for healthcare workers. And citing 3D printing, the director of a not-for-profit working with the government says the country has an "incredible onshore capability" to respond to the pandemic: "The 3D printing capability onshore is a massive distinguisher for Australia to step up to the crisis," he said. When asked how else 3D printing might be deployed in practice, Goennemann points to the supply of ventilators, which are needed to assist breathing in the most seriously ill Covid-19 patients... Goennemann says Resmed, the main ventilator manufacturer, could struggle to get parts due to the disruption of global supply chains. That's where 3D printing can help. "I don't want to speak on behalf of Resmed, but that's an area where we have critical supply, and parts can be 3D printed onshore rather than being procured offshore," he said...

For Bowtell, the decision to shift his production to face shields had nothing to do with profit. It was about doing what he could in the most extraordinary of times. "It's about survival at the moment," Bowtell said. "Just helping people to get through this together."
Reuters also reported that one Italian company used its 3D printers to manufacture valves for respirators for its local hospital. And a paywalled article at Fortune also describes the team building an open source ventilator, while also noting that more than 4,800 people with 3D printers "have, via a public Google Doc, signed up to help print everything from face shields to ventilator parts for their local hospitals."

They also highlight Budmen Industries, an upstate New York company selling 3D printers that has now also printed 1,492 face shields for New York medical workers. And finally there's the CoVent-19 Challenge, "an open innovation 8-week Grand Challenge for engineers, innovators, designers, and makers" on the GrabCAD Challenges platform, to create "a rapidly deployable, minimum viable mechanical ventilator for patients with COVID-19 related ventilator-dependent lung injury."

"Crowds flock to Santa Clara County test sites to learn if they have antibodies to COVID-19," reports the Bay Area Newsgroup, citing long lines of cars forming at three Stanford research sites for the drive-through tests: The 2,500 test slots on Friday and Saturday filled up within hours, as news of the project -- the first large scale study of its type in the U.S. -- spread quickly through the county. The test detects protective antibodies to the virus rather than the virus itself. This gives scientists a snapshot of how many people in the county have already been infected, but weren't seriously sick and didn't realize it. And it tells residents whether they carry potentially protective antibodies -- so may be immune to future infection. "This is critical information," said principal investigator Dr. Eran Bendavid, an infectious disease specialist and professor of medicine with Stanford Health Policy.

"We will show the country what to do and how to do it," he said... It can guide public health measures and policies -- showing where the epidemic is heading, when it is safe to lift shelter-in-place restrictions and how far away we are from "herd immunity," when it becomes harder for a virus to spread...

This approach, called a "serological test," remains a research tool and is not yet widely available in the United States. Stanford is working on a second test that will be deployed for more widespread use. U.S. Food and Drug Administration approval is imminent -- "within hours, not days," [California governor] Newsom said.... Meanwhile, a global effort to study antibodies is being coordinated by the World Health Organization. Called Solidarity II, more than a half dozen countries will pool their findings from large-scale testing...

It is not yet proven that these antibodies actually provide protection... But there are promising clues that COVID-19 might act like it's closest cousin, the SARS virus, which triggers an immune response that persists for at least three years. In a Chinese study of rhesus monkeys, COVID-19 antibodies protected the animals from a second infection.

If protected, people could potentially return to work. There is also the prospect that the antibodies could be used as therapy against the disease. Dozens of companies are working to develop antibody tests, as are researchers at the Centers for Disease Control and Prevention.
The article notes that United Biomedical Inc will "soon" also provide free antibody testing to all 8,000 residents in Telluride, Colorado, and in some countries in Asia.

Long-time Slashdot reader theodp writes: With the CDC now recommending wearing cloth face coverings in public settings, Etsy has called in the cavalry, encouraging additional sellers on its platform to start creating and offering face masks to help meet an already significant demand for fabric face masks. "We believe that the Etsy community is uniquely positioned to address this crucial need during a global health crisis," Etsy CEO Josh Silverman said in a statement. "We hope that increasing the availability of fabric, non-medical grade face masks from Etsy sellers will allow more medical and surgical masks to reach the people who need them most: front-line health care workers."

USA Today reports: Ohio Governor Mike DeWine Sunday afternoon said federal officials have promised to ease restrictions on a technology to clean and reuse the masks deemed the safest for healthcare workers and first responders in the coronavirus outbreak....

Officials are scrambling for the N95 masks and other protective equipment for health care workers as the number of COVID-19 cases is expected to spike over the coming months. On Saturday, DeWine publicly pleaded with the FDA to approve an emergency-use permit for [Columbus-based research firm] Battelle's technology amid a shortage of personal protective equipment, including masks.... The U.S. death total has doubled in two days, climbing above 2,300 Sunday. Dr. Anthony Fauci, who has been a leading voice in the effort to curb the outbreak, said 100,000 to 200,000 Americans could die before the crisis is over.

DeWine said those numbers make it urgent for the FDA to clean as many masks as it can... The Battelle process uses "vapor phase hydrogen peroxide" to sanitize the N95 masks, allowing them to be reused up to 20 times, the company said in a statement. Each of the company's Critical Care Decontamination Systems can sterilize 80,000 masks per day, Battelle said... DeWine on Sunday said the FDA authorized Battelle to sterilize just 10,000 surgical masks a day. "They're only approved a fraction of what we can do," DeWine said during the press conference.
But DeWine said in his afternoon press conference that an FDA commissioner told him "this would be cleared up today."

An anonymous reader quotes the Wall Street Journal: Government officials across the U.S. are using location data from millions of cellphones in a bid to better understand the movements of Americans during the coronavirus pandemic and how they may be affecting the spread of the disease...

The data comes from the mobile advertising industry rather than cellphone carriers. The aim is to create a portal for federal, state and local officials that contains geolocation data in what could be as many as 500 cities across the U.S., one of the people said, to help plan the epidemic response... It shows which retail establishments, parks and other public spaces are still drawing crowds that could risk accelerating the transmission of the virus, according to people familiar with the matter... The data can also reveal general levels of compliance with stay-at-home or shelter-in-place orders, according to experts inside and outside government, and help measure the pandemic's economic impact by revealing the drop-off in retail customers at stores, decreases in automobile miles driven and other economic metrics.

The CDC has started to get analyses based on location data through through an ad hoc coalition of tech companies and data providers — all working in conjunction with the White House and others in government, people said.

The CDC and the White House didn't respond to requests for comment.
It's the cellphone carriers turning over pandemic-fighting data in Germany, Austria, Spain, Belgium, the U.K., according to the article, while Israel mapped infections using its intelligence agencies' antiterrorism phone-tracking. But so far in the U.S., "the data being used has largely been drawn from the advertising industry.

"The mobile marketing industry has billions of geographic data points on hundreds of millions of U.S. cell mobile devices..."

While many coronavirus tests provide results within hours or days, America's Food and Drug Administration "has authorized the emergency use" of a new rapid coronavirus test from medical device manufacturer Abbott that could results in less than 15 minutes, reports NBC News: The FDA told Abbott it authorized the test's use after determining that "it is reasonable to believe that your product may be effective in diagnosing COVID-19," based on the scientific evidence presented. The agency added that the "known and potential benefits" of the test outweigh potential risks, such as false positives or negatives. The technology being used for the new test is similar to the one found in rapid flu tests, according to the FDA's authorization letter and Abbott.

The FDA also said Friday it has issued at least 19 other emergency use authorizations for diagnostic tests to detect COVID-19, and that it is working with more than 220 test developers who are expected to submit emergency-use authorization requests soon...

Abbott said it is ramping up production to deliver 50,000 tests to the U.S. health care system starting next week.

An anonymous reader quotes Wired: Next week, blood banks across the Netherlands are set to begin a nationwide experiment. As donations arrive — about 7,000 of them per week is the norm — they'll be screened with the usual battery of tests that keep the blood supply safe, plus one more: a test for antibodies to SARS-CoV-2, the virus that causes Covid-19. Then, in a few weeks, another batch of samples will get the same test. And after that, depending on the numbers, there could be further rounds. The blood donors should be fairly representative of Dutch adults ages 18 to 75, and most importantly, they'll all be healthy enough for blood donation — or at least outwardly so...

Identifying what proportion of the population has already been infected is key to making the right decisions about containment... [B]ecause no Covid-19-specific serological [antibody] tests have been fully vetted yet, the FDA's latest guidance is that they shouldn't be relied upon for diagnoses. But in epidemiology circles, those tests are a sought-after tool for understanding the scope of the disease. Since February — which was either three weeks or a lifetime ago — epidemiologists have been trying to get the full scope of the number of infections here in the U.S... [A]s the disease has continued to spread and a patchwork of local "stay at home" rules begins to bend the course of the disease, projecting who has the disease and where the hot spots are has become more difficult for models to capture.

Instead, you need boots-on-the-ground surveillance. In other words, to fill the gap created by a lack of diagnostic tests, you need more testing — but of a different sort. This time you have to know how many total people have already fought the bug, and how recently they've fought it. "Of all the data out there, if there was a good serological assay that was very specific about individuating recent cases, that would be the best data we could have," says Alex Perkins, an epidemiologist at the University of Notre Dame. The key, he says, is drawing blood from a representative sample that would show the true scope of unobserved infections... Another motivation to develop better blood tests is the potential to develop therapeutics from antibody-rich blood serum.
Wired is currently providing free access to stories about the coronavirus.

ZDNet reports that Singapore is fighting the coronavirus with a new smartphone app named "TraceTogether". The app is able to estimate the distance between TraceTogether smartphones as well as the duration of such interactions. The data then is captured, encrypted, and stored locally on the user's phone for 21 days, which spans the incubation period of the virus. When needed in contact tracing, users will have to authorise the uploading of their TraceTogether data to Singapore's Ministry of Health, which then will assess the information and retrieve the mobile numbers of close contacts within that period of time.

Developed by Government Technology Agency (GovTech), alongside the health ministry, the app was designed to help speed up the contact tracing process and stem the spread of COVID-19, the government IT office said. GovTech said the current processed depended heavily on the memory of patients, who might not be ale to remember all close contacts or have the contact details and information of these individuals. The mobile app can plug the gaps and more quickly identify potential carriers, who then can monitor their health and take the necessary action sooner...

Data logs were stored locally on the mobile phone and contained only cryptographically generated temporary IDs. The data logs would be extracted only when needed by the authorities for contact tracing, it said.

America's Food and Drug Administration has approved a coronavirus test from a company called Cepheid.

It can deliver its results in about 45 minutes, "much faster than current tests that require a sample to be sent to a centralized lab, where results can take days," reports The Hill: The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert Systems worldwide, of which 5,000 are in the U.S., the company said. The systems are already being used to test for conditions such as HIV and tuberculosis. The systems do not require users to have specialty training to perform testing and are capable of running around the clock.

"An accurate test delivered close to the patient can be transformative" and can "help alleviate the pressure" that the COVID-19 outbreak has put on health facilities, David Persing, Cepheid's chief medical and technology officer, said in a statement.

An anonymous reader quotes UPI: Scientists have developed a technique for repairing damaged DNA. The breakthrough, published this week in the journal Nature Communications, could pave the way for new therapies for cancer and neurodegenerative disorders.

The accumulation of DNA damage is responsible for aging, cancer and neurological diseases like motor neuron disease, also known as ALS.

Until now, scientists have struggled to find ways to repair this kind of damage. However, researchers have discovered a new protein called TEX264 that can combine with other enzymes to find and destroy toxic proteins that bind to DNA and trigger damage.

Scientists are hoping to identify ways to use TEX264 and its protein relatives to repair the DNA damage linked with disorders like cancer and ALS. New therapies inspired by the latest research could also be used to repair the purposeful DNA damage caused by chemotherapy.

schwit1 quotes the International Business Times: Swiss pharmaceutical giant Roche announced Friday it had received emergency approval from U.S. regulators for a new and much faster test for diagnosing the deadly new coronavirus...

The test can be run in high volumes on fully automated equipment, Roche said, suggesting it could provide more results far faster than other tests available. "We are increasing the speed definitely by a factor of 10," Thomas Schinecker, head of Roche's diagnostics unit, said in an interview with Bloomberg News. Widespread testing is essential in the race to rein in the spread of the virus, which has so far infected more than 130,000 people and killed nearly 5,000 worldwide. The new Roche tests, which will also now be available in markets that accept the European CE-mark certification, are run on Roche's widely available cobas 6800/8800 systems and can provide results within 3.5 hours, the company said.

In a 24-hour period, the largest machines can provide results on up to 4,128 tests, it said.
Fierce Biotech points out that "emergency use" of the test was quickly approved by U.S. regulators within 24 hours: In addition to the one-day approval, the FDA said it did not object to Roche pre-shipping its COVID-19 tests to laboratories ahead of time, so they could be used immediately following the authorization...

The test is designed to detect nucleic acid strands of the SARS-CoV-2 virus from nasal or oral swabs. However, the company said negative results do not preclude an infection and should be combined with clinical observations and the patient's history and contact with the disease...

"Roche is committed to delivering as many tests as possible and is going to the limits of our production capacity," the company said in a statement, and it expects to have millions of tests available per month.

Starting next week, Starbucks will roll out its spring menu in stores across Canada that will include a breakfast sandwich with Beyond Meat sausage. Engadget reports: Starbucks joins a growing list of brands that have added Beyond Meat's plant-based offerings to their menus. To date, those companies include McDonald's (also a Canadian pilot), KFC, Subway, Carl's Jr., Hardee's and more. The lab-grown, plant-based meat trend is a product of science and tech, but it's also driven by a growing awareness of the environmental impacts of meat production. Earlier this year, Starbucks said it was committed to a "resource-positive future," which includes expanding plant-based options and creating a more environmentally friendly menu. The upcoming egg, cheddar and Beyond Meat sausage breakfast sandwich is the first major step in that direction.

Singaporean company Shiok Meats aims to grow artificial shrimp to combat the negative environmental effects associated with farmed shrimp. An anonymous reader shares an excerpt from The Economist: For a long time, beef has been a target of environmentalists because of cattle farming's contribution to global warming. But what about humble shrimp and prawns? They may seem, well, shrimpy when compared with cows, but it turns out the tasty decapods are just as big an environmental problem. The issue is not so much their life cycle: shrimp (as UN statisticians refer to all commonly eaten species collectively) do not belch planet-cooking methane the way cows do. But shrimp farms tend to occupy coastal land that used to be covered in mangroves. Draining mangrove swamps to make way for aquaculture is even more harmful to the atmosphere than felling rainforest to provide pasture for cattle. A study conducted in 2017 by CIFOR, a research institute, found that in both these instances, by far the biggest contribution to the carbon footprint of the resulting beef or shrimp came from the clearing of the land. As a result, CIFOR concluded, a kilo of farmed shrimp was responsible for almost four times the greenhouse-gas emissions of a kilo of beef. Eating a surf-and-turf dinner of prawn cocktail and steak, the study warned, can be more polluting than driving across America in a petrol-fuelled car.

All this has given one Singaporean company a brain wave. "Farmed shrimps are often bred in overcrowded conditions and literally swimming in sewage water. We want to disrupt that -- to empower farmers with technology that is cleaner and more efficient," says Sandhya Sriram, one of the founders of Shiok Meats. The firm aims to grow artificial shrimp, much as some Western firms are seeking to create beef without cows. The process involves propagating shrimp cells in a nutrient-rich solution. Ms Sriram likens it to a brewery, disdaining the phrase "lab-grown." Since prawn-meat has a simpler structure than beef, it should be easier to replicate in this way. Moreover, shrimp is eaten in lots of forms and textures: whole, minced, as a paste and so on. The firm is already making shrimp mince which it has tested in Chinese dumplings. It hopes the by-product of the meat-growing can be used as a flavoring for prawn crackers and instant noodles. Eventually it plans to grow curved "whole" shrimp -- without the head and shell, that is. While producing shrimp this way currently costs $5,000 a kilo, Shiok Meats thinks it can bring the price down dramatically by using less rarefied ingredients in its growing solution.